GE HealthCare Technologies/$GEHC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GE HealthCare Technologies
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Ticker
$GEHC
Sector
Primary listing
Employees
53,000
Headquarters
Website
GEHC Metrics
BasicAdvanced
$35B
15.66
$4.88
1.29
$0.14
0.18%
Price and volume
Market cap
$35B
Beta
1.29
52-week high
$94.80
52-week low
$57.65
Average daily volume
3.3M
Dividend rate
$0.14
Financial strength
Current ratio
1.16
Quick ratio
0.832
Long term debt to equity
86.245
Total debt to equity
107.666
Dividend payout ratio (TTM)
2.63%
Interest coverage (TTM)
7.42%
Profitability
EBITDA (TTM)
3,674
Gross margin (TTM)
41.56%
Net profit margin (TTM)
11.22%
Operating margin (TTM)
15.56%
Effective tax rate (TTM)
17.17%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
5.77%
Return on equity (TTM)
25.80%
Valuation
Price to earnings (TTM)
15.664
Price to revenue (TTM)
1.748
Price to book
3.59
Price to tangible book (TTM)
-7.09
Price to free cash flow (TTM)
22.297
Free cash flow yield (TTM)
4.48%
Free cash flow per share (TTM)
3.428
Dividend yield (TTM)
0.18%
Forward dividend yield
0.18%
Growth
Revenue change (TTM)
2.31%
Earnings per share change (TTM)
41.40%
3-year revenue growth (CAGR)
4.06%
3-year earnings per share growth (CAGR)
4.31%
What the Analysts think about GEHC
Analyst ratings (Buy, Hold, Sell) for GE HealthCare Technologies stock.
Bulls say / Bears say
GE HealthCare’s second-quarter revenue of $5.01 billion and EPS of $1.06 easily topped consensus estimates of $4.97 billion and $0.92 respectively, demonstrating operational resilience and pricing power. (WSJ)
The company raised its full-year 2025 guidance to about 3% organic revenue growth with adjusted EPS forecast between $4.43 and $4.63 and free cash flow of at least $1.4 billion, reflecting confidence in healthy capital investment trends. (WSJ)
GE HealthCare secured a grant of over $44 million from the Bill & Melinda Gates Foundation to develop AI-assisted ultrasound technology, underscoring its leadership in innovation and next-generation product development. (Reuters)
Estimated $500 million in tariff costs for 2025 underscores persistent headwinds to GE HealthCare’s profitability despite ongoing mitigation efforts. (FT)
China sales declined 15% in 2024 and are expected to remain under pressure from delayed stimulus and anti-corruption campaigns, weighing on near-term growth prospects. (Reuters)
Free cash flow guidance of at least $1.4 billion remains well below the initial target of $1.75 billion for 2025, indicating reduced cash conversion expectations amid reimbursement and cost pressures. (WSJ)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
GEHC Financial Performance
Revenues and expenses
GEHC Earnings Performance
Company profitability
GEHC News
AllArticlesVideos
GE HealthCare announces intent to acquire icometrix to strengthen neurology portfolio with brain MRI assessment solutions
Business Wire4 days ago
GE HealthCare Enters an Agreement to Distribute Flyrcado Through CDL Nuclear Technologies Group, a Leading Provider of Cardiac PET Imaging Equipment and Services in the U.S.
Business Wire6 days ago
GE HealthCare unveils Vivid Pioneer, its most advanced AI-powered cardiovascular ultrasound system, designed to enhance speed and image quality for improved diagnostic confidence and workflow efficiency
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GE HealthCare Technologies stock?
GE HealthCare Technologies (GEHC) has a market cap of $35B as of September 14, 2025.
What is the P/E ratio for GE HealthCare Technologies stock?
The price to earnings (P/E) ratio for GE HealthCare Technologies (GEHC) stock is 15.66 as of September 14, 2025.
Does GE HealthCare Technologies stock pay dividends?
Yes, the GE HealthCare Technologies (GEHC) stock pays dividends to shareholders. As of September 14, 2025, the dividend rate is $0.135 and the yield is 0.18%. GE HealthCare Technologies has a payout ratio of 2.63% on a trailing twelve-month basis.
When is the next GE HealthCare Technologies dividend payment date?
The next GE HealthCare Technologies (GEHC) dividend payment date is unconfirmed.
What is the beta indicator for GE HealthCare Technologies?
GE HealthCare Technologies (GEHC) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.